Notably, first results from a randomized phase II/III study, the ALLIANCE051701 trial, of DA-EPOCH-R ± Venetoclax in the high-risk arena of MYC/BCL2 DH lymphomas was presented at the ASH 2021 annual meeting [100]. Here, BCL2 is linked to lymphoma.